Worcester, USA - 25 Sep `19Dermavant Sciences: Cerdulatinib Gel

Official Title: A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo. 

In Brief: Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks

Ages Eligible:  18 Years to 70 Years

Start Date: September 25, 2019

Completion Date (estimated): July 2020

Status: Active, recruiting

Study ID

  • ClinicalTrials.gov: NCT04103060
  • Other Study ID Numbers: DMVT-502-2101

Location: Dermavant Investigational Site: Worcester, Massachusetts, United States, 01605

Contact: To learn more about this study, you or your doctor may contact Dermavant Sciences by phone +1-480-666-0844 or email dermavantclinicaltrials@dermavant.com. Please refer to this study by its ClinicalTrials.gov identifier (NCT number)

FAQOther Questions

  • Vitiligo and hearing loss: any connection?

    In short, NO. Recent research shows no relationship between a degree of skin depigmentation and hearing loss severity in vitiligo patients. The results of this study showed tha...

  • Will it spread?

    Vitiligo activity may vary considerably from person to person. In a good number of patients the disease goes on for 3-4 years and then it settles down, with one or two stubborn...

  • Can a gluten-free diet help with vitiligo?

    It's very unlikely. We have specifically looked into claims that gluten-free diet may ease symptoms of vitiligo, or completely reverse it, and found no firm scientific evidence ...